Press Releases
New modalities hog the limelight
There has been continuous demand for the production of more complex mAbs and recombinant proteins, such as bispecifics, multispecifics, and antibody-drug conjugates, as CDMOs expand and diversify their service scope to new modalities.
In this Contract Pharma article, Jisun Choi, a lead specialist in our Market Intelligence Group, shares her insights on latest market trends and how Samsung Biologics is offering tailored services to meet the needs of each client.
Read more
There has been continuous demand for the production of more complex mAbs and recombinant proteins, such as bispecifics, multispecifics, and antibody-drug conjugates, as CDMOs expand and diversify their service scope to new modalities.
In this Contract Pharma article, Jisun Choi, a lead specialist in our Market Intelligence Group, shares her insights on latest market trends and how Samsung Biologics is offering tailored services to meet the needs of each client.
Read more